Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 31Lung Neoplasms 11Head and Neck Neoplasms 5Breast Neoplasms 3Adenocarcinoma of Lung 3Squamous Cell Carcinoma of Head and Neck 2Skin Neoplasms 2Prostatic Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Gliosarcoma 2Glioblastoma 2Esophageal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma 2Brain Neoplasms 2Adenocarcinoma Of Esophagus 2Urinary Bladder Neoplasms 1Untreated Childhood Anaplastic Astrocytoma 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Salivary Gland Neoplasms 1Recurrence 1Pleural Effusion, Malignant 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Neoplasms, Squamous Cell 1Lymphoid Interstitial Pneumonia 1Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer 1

Interventions

Paclitaxel 96Carboplatin 81Bevacizumab 62Gemcitabine 36liposomal doxorubicin 32pembrolizumab 30Topotecan 26olaparib 23Taxes 23niraparib 17Immunoglobulin G 17Disulfides 17Docetaxel 16Cyclophosphamide 16Cisplatin 14Nivolumab 11rucaparib 10durvalumab 10Doxorubicin 9Albumin-Bound Paclitaxel 8sargramostim 7pazopanib 7fludarabine phosphate 7fludarabine 7avelumab 7Magnetic Resonance Spectroscopy 7Ifosfamide 7epacadostat 6Trabectedin 6Sorafenib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Ovarian Neoplasms × Gefitinib × Clear all
NCT00317772 2022-02-07

Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer

M.D. Anderson Cancer Center

Phase 1/2 Completed
19 enrolled 12 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡